San Diego, CA (June 14, 2016)—Suneva Medical, Inc., a privately-held and innovative aesthetics leader, today announced the closing of a $25 million investment by Essex Woodlands. This financing strengthens Suneva Medical’s rapid revenue growth and further supports the ongoing commercialization of the company’s flagship products, Bellafill® and Regenica®.

Bellafill® is the only FDA approved dermal filler for the treatment of nasolabial folds, or smile lines, with five-year data for safety, effectiveness and patient satisfaction. It is also the only FDA approved dermal filler for the treatment of facial acne scars, representing a significant clinical advancement for a skin condition that previously had limited treatment choices. The Regenica® skin care line is formulated with the most advanced growth factor technology to enhance skin’s natural repair and renewal mechanisms.

“The expansion of the aesthetics market continues to grow across the United States. With two differentiated indications for Bellafill® and a next generation growth factor product in Regenica®, Suneva Medical is uniquely positioned to be a standout in the aesthetics industry,” said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. “The additional funding from Essex Woodlands fortifies our position and allows us to further accelerate the strong momentum of the business which remains committed to product innovation backed by rigorous scientific data.”

Martin Sutter, Managing Director and Co-Founder of Essex Woodlands, also commented on the investment: “We are pleased to be supporting Nick Teti and the management team as they continue the successful growth trajectories of Bellafill® and Regenica®. Suneva’s differentiated products are uniquely situated to take advantage of the tailwinds in the aesthetics market. We are excited to be a part of the growth of the company.”

In conjunction with the investment, Essex Woodlands will receive one seat on Suneva Medical’s board of directors and an independent seat will also be appointed. In addition to Essex Woodlands, other major equity shareholders include HealthCare Royalty Partners, Almirall, S.A. and Polaris Partners.

Leerink Partners LLC acted as the exclusive placement agent to the company for the offering.

With $2.5 billion under management, Essex Woodlands is one of the largest and oldest growth equity firms pursuing investments in pharmaceuticals, medical devices, healthcare services and healthcare information technology. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing and/or management of over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York and London. For more information, please see www.ewhv.com.

About Suneva Medical, Inc.

Suneva Medical is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. The company markets Bellafill® in the U.S., Canada and Hong Kong; ArteFill® in South Korea; Regenica® skin care in the U.S., Canada and Hong Kong; and ReFissa® tretinoin cream in the U.S. ArteFill® was rebranded to Bellafill® in the U.S. to reflect the transformational outcomes this unique product can provide to patients seeking correction of their acne scars and nasolabial folds. For more information, visit www.sunevamedical.com.